J Korean Med Assoc.  2015 May;58(5):398-407. 10.5124/jkma.2015.58.5.398.

The Korean guideline for cervical cancer screening

• Min KJ
• Lee YJ
• Suh M
• Yoo CW
• Lim MC
• Choi J
• Ki M
• Kim YM
• Kim JW
• Kim JH
• Park EW
• Lee HY
• Lim SC
• Cho CH
• Hong SR
• Dang JY
• Kim SY
• Kim Y
• Lee WC
• Lee JK

• KMID: 2195036
• DOI: http://doi.org/10.5124/jkma.2015.58.5.398

Abstract

The incidence rate of cervical cancer in Korea is still higher than in other developed countries, notwithstanding the national mass screening program. Furthermore, a new method has been introduced in cervical cancer screening. Therefore, the committee for cervical cancer screening in Korea updated the recommendation statement established in 2002. The new version of the guideline was developed by the committee using evidence-based methods. The committee reviewed the evidence for the benefits and harms of the Papanicolaou test, liquid-based cytology, and human papilloma virus (HPV) testing, and reached conclusions after deliberation. The committee recommends screening for cervical cancer with cytology (papanicolaou test or liquid-based cytology) every three years in women older than 20 years of age (recommendation A). The combination test (cytology with HPV test) is optionally recommended after taking into consideration individual risk or preference (recommendation C). The current evidence for primary HPV screening is insufficient to assess the benefits and harms of cervical cancer screening (recommendation I). Cervical cancer screening can be terminated at the age of 74 years if more than three consecutive negative cytology reports have been confirmed within ten years (recommendation D).

Keyword

Papanicolaou test; Mass screening; Uterine cervical neoplasms

MeSH Terms

Developed Countries
Female
Humans
Incidence
Korea
Mass Screening*
Papanicolaou Test
Papilloma
Uterine Cervical Neoplasms*

Figure

• 

  Figure 1 Framework of developing a guideline for cervical cancer screening. ①Benefits of pap test screening, ②harms of pap test screening, ③accuracy and harm of liquid based cytology, ④benefits of HPV primary test or cotest, ⑤harms of HPV primary test or cotest, ⑥target age and interval of cervical cancer screening, ⑦specific population group for cervical cancer. HPV, human papilloma virus; LBC, liquid-based cytology.

• 

  Figure 2 Flow of guideline searching.

Reference

1. Moyer VA. U.S. Preventive Services Task Force. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012; 156:880–891.

2. Dickinson J, Tsakonas E, Conner Gorber S, Lewin G, Shaw E, Singh H, Joffres M, Birtwhistle R, Tonelli M, Mai V, McLachlin M. Canadian Task Force on Preventive Health Care. Recommendations on screening for cervical cancer. CMAJ. 2013; 185:35–45.

3. Lee JK, Hong JH, Kang S, Kim DY, Kim BG, Kim SH, Kim YM, Kim JW, Kim JH, Kim TJ, Kim HJ, Kim HS, Ryu HS, Song JY, Ahn HS, Yoo CW, Yoon HK, Lee KH, Lee A, Lee Y, Lee IH, Lee JW, Lee TS, Lim MC, Chang SJ, Chung HH, Ju W, Joo HJ, Hur SY, Hong SR, Nam JH. Practice guidelines for the early detection of cervical cancer in Korea: Korean Society of Gynecologic Oncology and the Korean Society for Cytopathology 2012 edition. J Gynecol Oncol. 2013; 24:186–203.

4. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, Garcia FA, Moriarty AT, Waxman AG, Wilbur DC, Wentzensen N, Downs LS Jr, Spitzer M, Moscicki AB, Franco EL, Stoler MH, Schiffman M, Castle PE, Myers ER. ACS-ASCCP-ASCP Cervical Cancer Guideline Committee. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012; 62:147–172.

5. Committee on Practice Bulletins-Gynecology. ACOG Practice Bulletin Number 131: screening for cervical cancer. Obstet Gynecol. 2012; 120:1222–1238.

6. Murphy J, Kennedy EB, Dunn S, McLachlin CM, Fung Kee, Gzik D, Shier M, Paszat L. Ontario Cervical Screening Program. Program in Evidence-based Care. Cervical screening: a guideline for clinical practice in Ontario. J Obstet Gynaecol Can. 2012; 34:453–458.

7. Partridge EE, Abu-Rustum NR, Campos SM, Fahey PJ, Farmer M, Garcia RL, Giuliano A, Jones HW 3rd, Lele SM, Lieberman RW, Massad SL, Morgan MA, Reynolds RK, Rhodes HE, Singh DK, Smith-McCune K, Teng N, Trimble CL, Valea F, Wilczynski S. National Comprehensive Cancer Networks. Cervical cancer screening. J Natl Compr Canc Netw. 2010; 8:1358–1386.

8. Hamashima C, Aoki D, Miyagi E, Saito E, Nakayama T, Sagawa M, Saito H, Sobue T. Japanese Research Group for Development of Cervical Cancer Screening Guidelines. The Japanese guideline for cervical cancer screening. Jpn J Clin Oncol. 2010; 40:485–502.

9. Royal Australian College of General Practitioners. Early detection of cancers. Guidelines for preventive activities in general practice. 8th ed. East Melbourne: Royal Australian College of General Practitioners;2012. p. 60–72.

10. Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, Fervers B, Graham ID, Grimshaw J, Hanna SE, Littlejohns P, Makarski J, Zitzelsberger L. AGREE Next Steps Consortium. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ. 2010; 182:E839–E842.

11. Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, Hingmire S, Malvi SG, Thorat R, Kothari A, Chinoy R, Kelkar R, Kane S, Desai S, Keskar VR, Rajeshwarkar R, Panse N, Dinshaw KA. HPV screening for cervical cancer in rural India. N Engl J Med. 2009; 360:1385–1394.

12. Herbert A, Stein K, Bryant TN, Breen C, Old P. Relation between the incidence of invasive cervical cancer and the screening interval: is a five year interval too long? J Med Screen. 1996; 3:140–145.

13. Andrae B, Kemetli L, Sparen P, Silfverdal L, Strander B, Ryd W, Dillner J, Tornberg S. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J Natl Cancer Inst. 2008; 100:622–629.

14. Aristizabal N, Cuello C, Correa P, Collazos T, Haenszel W. The impact of vaginal cytology on cervical cancer risks in Cali, Colombia. Int J Cancer. 1984; 34:5–9.

15. Berrino F, Gatta G, d'Alto M, Crosignani P, Riboli E. Efficacy of screening in preventing invasive cervical cancer: a case-control study in Milan, Italy. IARC Sci Publ. 1986; (76):111–123.

16. Clarke EA, Anderson TW. Does screening by "Pap" smears help prevent cervical cancer? A case-control study. Lancet. 1979; 2:1–4.

17. Decker K, Demers A, Chateau D, Musto G, Nugent Z, Lotocki R, Harrison M. Papanicolaou test utilization and frequency of screening opportunities among women diagnosed with cervical cancer. Open Med. 2009; 3:e140–e147.

18. Hernandez-Avila M, Lazcano-Ponce EC, de Ruiz PA, Romieu I. Evaluation of the cervical cancer screening programme in Mexico: a population-based case-control study. Int J Epidemiol. 1998; 27:370–376.

19. Herrero R, Brinton LA, Reeves WC, Brenes MM, de Britton RC, Gaitan E, Tenorio F. Screening for cervical cancer in Latin America: a case-control study. Int J Epidemiol. 1992; 21:1050–1056.

20. Hoffman M, Cooper D, Carrara H, Rosenberg L, Kelly J, Stander I, Williamson AL, Denny L, du Toit G, Shapiro S. Limited Pap screening associated with reduced risk of cervical cancer in South Africa. Int J Epidemiol. 2003; 32:573–577.

21. Jimenez-Perez M, Thomas DB. Has the use of pap smears reduced the risk of invasive cervical cancer in Guadalajara, Mexico? Int J Cancer. 1999; 82:804–809.

22. Makino H, Sato S, Yajima A, Komatsu S, Fukao A. Evaluation of the effectiveness of cervical cancer screening: a case-control study in Miyagi, Japan. Tohoku J Exp Med. 1995; 175:171–178.

23. Nieminen P, Kallio M, Anttila A, Hakama M. Organised vs. spontaneous Pap-smear screening for cervical cancer: a case-control study. Int J Cancer. 1999; 83:55–58.

24. Talbott EO, Norman SA, Kuller LH, Ishii EK, Baffone KM, Dunn MS, Krampe BR, Weinberg GB. Refining preventive strategies for invasive cervical cancer: a population-based case-control study. J Womens Health (Larchmt). 1995; 4:387–395.

25. Cho BR. Evaluation of the validity of current national health screening program and plan to improve the system. Cheongju: Korea Centers for Disease Control and Prevention;2013.

26. Jun JK, Choi KS, Jung KW, Lee HY, Gapstur SM, Park EC, Yoo KY. Effectiveness of an organized cervical cancer screening program in Korea: results from a cohort study. Int J Cancer. 2009; 124:188–193.

27. Siebers AG, Klinkhamer PJ, Grefte JM, Massuger LF, Vedder JE, Beijers-Broos A, Bulten J, Arbyn M. Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: a randomized controlled trial. JAMA. 2009; 302:1757–1764.

28. Ronco G, Cuzick J, Pierotti P, Cariaggi MP, Dalla Palma P, Naldoni C, Ghiringhello B, Giorgi-Rossi P, Minucci D, Parisio F, Pojer A, Schiboni ML, Sintoni C, Zorzi M, Segnan N, Confortini M. Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial. BMJ. 2007; 335:28.

29. Taylor S, Kuhn L, Dupree W, Denny L, De Souza M, Wright TC Jr. Direct comparison of liquid-based and conventional cytology in a South African screening trial. Int J Cancer. 2006; 118:957–962.

30. Coste J, Cochand-Priollet B, de Cremoux P, Le Gales C, Cartier I, Molinie V, Labbe S, Vacher-Lavenu MC, Vielh P. French Society of Clinical Cytology Study Group. Cross sectional study of conventional cervical smear, monolayer cytology, and human papillomavirus DNA testing for cervical cancer screening. BMJ. 2003; 326:733.

31. Ko MJ, Kim Y, Hong SR, Lee JK, Shim J, Kim J, Choi SM, Lee YJ, Koh JS, Kim DY, Sung SH, Park H, Yoo CW, Lee KH, Lee JW, Chae SW. Cost-effectiveness of conventional cytology and HPV DNA testing for cervical cancer screening in South Korea. Seoul: National Evidence-based Healthcare Collaborating Agency;2014.

32. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Ghiringhello B, Girlando S, Gillio-Tos A, De Marco L, Naldoni C, Pierotti P, Rizzolo R, Schincaglia P, Zorzi M, Zappa M, Segnan N, Cuzick J. New Technologies for Cervical Cancer screening (NTCC) Working Group. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010; 11:249–257.

33. Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, Voorhorst FJ, Verheijen RH, van Groningen K, Boon ME, Ruitinga W, van Ballegooijen M, Snijders PJ, Meijer CJ. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007; 370:1764–1772.

34. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, Radberg T, Strander B, Johansson B, Forslund O, Hansson BG, Rylander E, Dillner J. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med. 2007; 357:1589–1597.

35. Kitchener HC, Almonte M, Thomson C, Wheeler P, Sargent A, Stoykova B, Gilham C, Baysson H, Roberts C, Dowie R, Desai M, Mather J, Bailey A, Turner A, Moss S, Peto J. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol. 2009; 10:672–682.